Question and Answer session with our General Manager
Some key questions were posed to our General Manager, Alex Chapman to find out his thoughts on his role, the company and Labskin. We managed to find some time with him in his busy schedule and ask these questions………
Describe your typical day as the General Manager at Innovenn.
A typical day is extremely varied and depends on what customer interactions are occurring at the time and will influence the whole day, but generally there is usually a mixture of working through projects with different customers, which can all be at various stages from initial conversations through quotes to reporting. There is quite a lot of work required on reviewing the financial aspects of supplying services and Labskin to large companies, this can take quite a lot of time. Internally, I keep the team up to date with the various external activities and respond to any internal issues that arises. I am also actively involved in the Sales and Marketing aspect of the company where I produce and update marketing material such as application notes, the website and things like that.
What has surprised you the most since starting at Innovenn?
The most surprising aspect since joining would be the amount of work required on evaluating and continually assessing the company’s finances. There is a lot more interaction with our parent company Integumen and our suppliers and customers, which I didn’t appreciate beforehand.
What is your favourite part of your role?
I’m still relatively new to the role and this area of science, but there is always something new to address. It can sometimes it can be frustrating, particularly when you need to resolve issues revolving around the shipment of Labskin into certain countries, but I love learning something new and this job provides me with that opportunity.
What do you see Innovenn becoming and evolving into?
For me, our unique offering of our in-depth understanding of Labskin makes it an ideal research tool so I see Labskin and Innovenn becoming a key research partner for our customers. We are already moving into the direction of using the model to assess skin metabolism and drug penetration, as well as creating healthy and diseased models. I truly believe our future will be providing the model to the scientific community as a medium throughput in-depth research platform.